Pages that link to "Q38786027"

The following pages link to Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study (Q38786027):

Displaying 47 items.

• Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. (Q45324737) (← links)
• Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination (Q45325786) (← links)
• Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (Q47547989) (← links)
• Hepatitis C Transmission from Seropositive, Non-Viremic Donors to Non-Hepatitis C Liver Transplant Recipients. (Q47569545) (← links)
• Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection (Q49911983) (← links)
• HCV Therapy in Decompensated Cirrhosis before or after Liver Transplantation: A Paradoxical Quandary (Q50067192) (← links)
• What do clinicians need to watch for with direct-acting antiviral therapy? (Q52327014) (← links)
• Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection (Q52577714) (← links)
• Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal. (Q52584959) (← links)
• Hepatitis C: Current Controversies and Future Potential in Solid Organ Transplantation. (Q54201712) (← links)
• 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. (Q54238865) (← links)
• Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. (Q54245484) (← links)
• Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. (Q54261696) (← links)
• Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. (Q55056866) (← links)
• Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients. (Q55508515) (← links)
• Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation (Q56654941) (← links)
• SVR is Associated with a Decreased Risk of Post-Transplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C Related Liver Disease (Q57020681) (← links)
• Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience (Q57213140) (← links)
• Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey (Q58423262) (← links)
• Use of hepatitis C viraemic organs in kidney transplantation: a need to hit the pause button? (Q58547280) (← links)
• Hepatitis C and renal transplantation in era of new antiviral agents (Q58792851) (← links)
• The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study (Q59349099) (← links)
• Hepatitis C virus and the kidney (Q59350550) (← links)
• Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of inf (Q59351915) (← links)
• Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of inf (Q59351917) (← links)
• Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of inf (Q59351919) (← links)
• Solid Organ Transplantation for HIV-Infected Individuals (Q59357554) (← links)
• Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. (Q64892074) (← links)
• Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. (Q64968302) (← links)
• A cross-sectional analysis of long-term immunosuppressive regimens after liver transplantation at Asan Medical Center: Increased preference for mycophenolate mofetil (Q88046514) (← links)
• Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA (Q88847691) (← links)
• Direct-acting Antivirals for the Treatment of Kidney Transplant Patients With Chronic Hepatitis C Virus Infection in Spain: A Long-term Prospective Observational Study (Q89869468) (← links)
• Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study (Q90079314) (← links)
• Eliminating Hepatitis C Virus From a Prevalent Kidney Transplant Recipient Population: A Single-Center Study in Belgium in the Direct-Acting Antivirals Era (Q90115984) (← links)
• APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? (Q90420437) (← links)
• Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis (Q90583935) (← links)
• Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site (Q90743981) (← links)
• Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy (Q91785581) (← links)
• The Reliability of Fibro-test in Staging Orthotopic Liver Transplant Recipients with Recurrent Hepatitis C (Q91795092) (← links)
• Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (Q91801771) (← links)
• Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update (Q92203399) (← links)
• Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation (Q92306840) (← links)
• Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center (Q92469821) (← links)
• Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions (Q92625996) (← links)
• Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease (Q92707561) (← links)
• Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study (Q94551467) (← links)
• Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis (Q99637206) (← links)